ThromboGenics’ JETREA® Receives Reimbursement in Spain
Leuven, September 1, 2014 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the Spanish Ministry of Health has approved the reimbursement of JETREA® (ocriplasmin) for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
JETREA® will be included in the national list of available reimbursed products from September, at a regional and hospital level. ThromboGenics’ partner Alcon holds the commercialization rights to JETREA® outside the US and will be responsible for the launch of the drug in Spain.
JETREA® is the first pharmacological treatment for this indication and was approved by the European Commission in the European Union in March 2013.